Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis

[11] Chaggar K(2004)Low dose hepatitis B immunoglobulin given ‘on demand’ in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation Transplantation 77 1203-1208

[12] Alexander GJ(2004)Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation Antivir Ther 9 921-927

[13] Williams R(2007)Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation Transplantation 83 231-233

[14] O’Grady JG(2003)HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis Hepatology 38 86-95

[15] Smith HM(2002)Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load J Clin Microbiol 40 439-445

[16] Davies SE(2005)Hepatitis B virus DNA-negative Dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain J Biol Chem 280 21713-21719

[17] Daniels HM(2009)Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients J Med Virol 81 27-33

[18] Donaldson PT(2004)Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy Gastroenterology 126 1750-1758

[19] Tan KC(1991)Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization J Hepatol 13 90-96

[20] Portmann B(1993)Liver transplantation in European patients with the hepatitis B surface antigen N Engl J Med 329 1842-1847

[11] Chaggar K(2004)Low dose hepatitis B immunoglobulin given ‘on demand’ in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation Transplantation 77 1203-1208

[12] Alexander GJ(2004)Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation Antivir Ther 9 921-927

[13] Williams R(2007)Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation Transplantation 83 231-233

[14] O’Grady JG(2003)HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis Hepatology 38 86-95

[15] Smith HM(2002)Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load J Clin Microbiol 40 439-445

[16] Davies SE(2005)Hepatitis B virus DNA-negative Dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain J Biol Chem 280 21713-21719

[17] Daniels HM(2009)Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients J Med Virol 81 27-33

[18] Donaldson PT(2004)Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy Gastroenterology 126 1750-1758

[19] Tan KC(1991)Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization J Hepatol 13 90-96

[20] Portmann B(1993)Liver transplantation in European patients with the hepatitis B surface antigen N Engl J Med 329 1842-1847